Merck Serono and Domain Therapeutics Partner to Develop Positive Allosteric Modulators for Parkinson’s Disease
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 1 (Table of Contents)
Published: 31 Jan-2011
DOI: 10.3833/pdr.v2011.i1.1426 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Highlighting the continued interest of the pharmaceutical industry in neurodegenerative diseases and G-protein coupled receptors (GPCRs), Merck Serono and Domain Therapeutics have partnered to develop metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) drugs for Parkinson’s disease and other neurodegenerative diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS